Immunic Inc
Research Immunic Inc (IMUX) on Bullrun: market cap USD 108.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMUX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 108.47M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 34.10M
- Free cash flow-USD 31.25M
Valuation Snapshot
latest market cap is USD 108.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 97.17M | -USD 85.97M | n/a | -0.62 | USD 15.48M | USD 577.00K | -USD 6.67M |
| FY2024 | USD 0 | -USD 100.51M | -USD 85.03M | n/a | -1 | USD 35.67M | USD 1.00M | USD 18.43M |
| FY2023 | USD 0 | -USD 93.61M | -USD 71.16M | n/a | -2.11 | USD 46.67M | USD 1.33M | USD 28.93M |
| FY2022 | USD 0 | -USD 120.41M | -USD 65.26M | n/a | -3.78 | USD 106.75M | USD 1.56M | USD 113.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 108.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 64.28M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 90.15M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 67.72M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 62.10M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 252.03M | n/a | n/a | n/a |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunic Inc's market cap?
Immunic Inc's market capitalization is USD 108.47M.
What does Immunic Inc do?
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.